Med-Mastodon - the instance - is over
Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease?
REACT: El Resumen Visual
REACT aterriza a #NephJC
Esta vez analizamos rilparencel, una terapia celular renal autóloga inyectada directamente en la corteza renal para enlentecer la perdida de la función renal en nefropatía diabética y ERC avanzada.
¿Estamos ante una nueva era en la nefrología?
Revisa el resumen visual por Natalia Nombera y únete a la discusión en #NephJC.
REACT: The Visual Abstract
REACT has landed to NephJC.
This time we explore rilparencel, an autologous kidney cell therapy injected directly into the renal cortex to slow kidney function decline in DKD and advanced CKD.
Is this the future of regenerative nephrology?
Take a look at the Visual Abstract Natalia Nombera and join the conversation on #NephJC.
2026 #NephJCKidneys vote begins
After an extended nomination period, it is time to vote for your favorites. Like in the previous years, you will need to be a subscriber to the newsletter to be eligible to vote. By voting you let our content creators know how much they are contributing the the FOAMed goals of NephJC.
Just one week to vote!
The link to vote will be available in the newsletter.
Here is the final ballot:
Article of the Year
PISCES trial: link| NephJC summary| Freely Filtered episode
ACHIEVE trial- spironolactone in dialysis: link| NephJC summary| Freely Filtered episode
VALIANT trial - pegcetacoplan in C3GN : link| NephJC summary
ORIGIN3 trial- atacicept in IgAN: link| NephJC summary| Freely Filtered episode
Primary aldosteronism underdiagnosed: link| NephJC summary
ADPKD KDIGO guideline: link| NephJC summary| Freely Filtered episode
REGENCY trial:- obinutuzumab in lupus nephritis link| NephJC summary| Freely Filtered episode
Metformin in advanced CKD: link| NephJC summary| Freely Filtered episode
HiLo- high vs low phosphorus target in dialysis: link| NephJC summary
Engaged Scientist of the Year
Jonathan Barratt @IgAN_JBarratt
Jordy Cohen @jordybc.bsky.social
Charmaine Lok - PISCES
Daniel Edmonston @danieledmonston.bsky.social
Nathan Hellman Social Media Project of the Year
ISN social media team for Spaces
Indian society of nephrology - social media team
Roger Rodby for Renal Biopsy Cases
Sophia Ambruso for abckidney.com
Most Valuable Player
Milagros Flores @dramiliflores.bsky.social
Brian Rifkin @brianrifkin.bsky.social
Akshaya Jaychandran @nephromommy-akshu.bsky.social
Visual Abstract of the Year
ISN-GKHA interactive map: From data to dialogue by Denisse Arellano
Akshaya Jaychandran ACHIEVE trial
Husam Alzayer: incremental dialysis
Krithika Mohan: herb nephropathy
NephJC Social Justice Award
WHO kidney resolution and UN political declaration
World KIdney Day- Kidney health for all
Dialysis delay at what cost? Protein restriction as a distraction in the age of GDMT
2026 KDIGO Anemia Management Guidelines
KDIGO 2026 Anemia in CKD: The Visual Abstract
Anemia remains a central challenge in chronic kidney disease, influencing quality of life, cardiovascular risk, and clinical outcomes. The updated KDIGO 2026 guideline provides practical recommendations on iron management, ESAs, HIF-PHIs, and transfusion strategies, emphasizing individualized care and risk–benefit assessment.
Take a quick look at the VA by Michelle Fravel summarizing the key concepts and clinical take-home message
KDIGO 2026 Anemia en la ERC: El Resumen Visual
La anemia continúa siendo un reto clave en la enfermedad renal crónica, con impacto directo en la calidad de vida, el riesgo cardiovascular y los desenlaces clínicos. La actualización KDIGO 2026 ofrece recomendaciones prácticas sobre el manejo del hierro, el uso de AEEs, PHI-HIFs y estrategias de transfusión, con énfasis en una toma de decisiones individualizada basada en riesgo-beneficio.
Revisa el resumen visual realizado por Michelle Fravel , donde resume los mensajes clave y las principales perlas clínicas de la guía 2026.
INFINITI: The Visual Abstract
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar
INFINITI: El Resumen Visual
Los iSGLT2 han revolucionado la protección cardiorrenal, pero los trasplantados renales han quedado fuera de la historia. El ensayo INFINITI empieza a cerrar esa brecha. ¿Flozinaran igual los iSGLT2 en el riñón trasplantado? Revisa el resumen visual creado por Janany Sabescumar
To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
NephJC on Instagram
NephJC continues to host its live journal clubs and real-time discussions on Bluesky where open dialogue, shared learning, and critical appraisal are central to what we do. For now, our scheduled chats and discussions will continue on Bluesky.
We are also expanding our presence on Instagram with a complementary goal. Instagram allows us to connect with nephrologists and the public who may not be active on X or Bluesky but who are still interested in practice-relevant research, methodology, and staying informed on ongoing NephJC activities. For many clinicians, Instagram serves as an accessible entry point rather than a space for in-depth discussion.
The NephJC editorial team recognizes that Instagram does not allow for the same type of open, back-and-forth dialogue that defines our journal clubs. We are not aiming to replicate that experience there. Instead, we see Instagram as a way to highlight important studies, share key concepts, and guide interested readers toward platforms where deeper discussion and engagement are possible.
Our commitment to thoughtful, inclusive, and rigorous discussion remains the same. Instagram is simply another way to welcome more colleagues into the NephJC community.
POTCAST- K+ Pop and Arrhythmia Drop
POTCAST: El Resumen Visual
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones? POTCAST desafía nuestro miedo al potasio.
Revisa el resumen visual por Jeyakumar Meyyappan y únete a la conversación en #NephJC
POTCAST: The Visual Abstract
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
TenPosts: pegcetacoplan in C3GN
Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.
A ray of hope APPEARS for C3G
A VALIANT effort to combat complement disorders with pegcetacoplan
VALIANT: El Resumen Visual
El ensayo clínico aleatorizado fase 3 VALIANT demostró que la inhibición proximal de C3 con pegcetacoplan logra una reducción significativamente mayor de la proteinuria en comparación con placebo en pacientes con glomerulopatía C3 (C3G) y glomerulonefritis membranoproliferativa primaria mediada por complejos inmunes (IC-MPGN). Este estudio se basa en estrategias previas de inhibición proximal del complemento y refuerza el papel de las terapias dirigidas a la fisiopatología en la C3G.
No te pierdas el resumen visual creado por Dra. Akshaya Jayachandran y súmate a la discusión en #NephJC por Bluesky 🦋